-
2024-515226-81-00
5
2022-06-02
Myocardial Injury after Noncardiac Surgery
-
2023-506359-68-00
5
2022-04-08
Active Proliferative Lupus Nephritis
-
2023-506771-10-00
5
2022-03-11
Breast Neoplasm, Neoplasm Metastasis
-
2023-503826-37-00
5
2022-02-11
Unresectable locally-advanced or metastatic HER2+ breast cancer
-
2023-509133-39-00
5
2021-11-29
Hormone receptor positive, HER2-negative advanced breast cancer
-
2024-510588-53-00
11
2021-06-10
Treatment of patients with HER2-positive breast cancer with or without
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer
-
2023-509358-72-00
5
2020-11-23
Diffuse large B-cell lymphoma
-
2024-511646-40-00
9
2019-07-11
First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the su
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2024-513912-89-00
10
2018-12-13
Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
-
2023-508018-41-00
4
2018-07-27
Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential
-
2023-509671-17-00
5
2017-07-12
Breast Cancer
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2023-509348-84-00
5
2015-04-27
Chronic Lymphocytic Leukemia
-
2023-507705-34-00
5
2025-08-29
Moderate to Severe Active Ulcerative Colitis
-
2024-510826-16-00
5
2025-04-07
Rheumatoid Arthritis
-
2023-507243-11-02
4
2025-01-05
Cardiogenic Shock
-
2024-515060-32-00
5
2024-11-22
Takotsubo syndrome
-
2023-506664-14-00
5
2024-10-24
Rheumatoid Arthritis
-
2023-506655-19-00
4
2024-05-16
Ulcerative Colitis (UC)
-
2023-507009-32-00
5
2024-05-08
General anaesthesia
-
2023-506084-34-00
5
2024-04-12
Type 2 Diabetes
-
2023-504564-42-00
4
2024-04-08
Moderate to Severe Rheumatoid Arthritis